Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GH Research PLC (GHRS : NSDQ)

• Company Description    GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $10.15 Daily Weekly Monthly 20 Day Moving Average: 102,073 shares Shares Outstanding: 50.52 (millions) Market Capitalization: $512.79 (millions) Beta: 52 Week High: $30.43 52 Week Low: $9.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -46.80% -41.71% 12 Week -43.80% -39.02% Year To Date -56.49% -48.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 28 BAGGOT STREET - LOWER DUBLIN,L2 2D02 NX43 IRL ph: 353-1437-8443 fax: - investors@ghres.com http://www.ghres.com

• General Corporate Information    Officers Theis Terwey - Chief Executive Officer Florian Schonharting - Chairman Michael Forer - Vice Chairman Julie Ryan - Vice President; Finance Dermot Hanley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G3855L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/27/22 Share - Related Items Shares Outstanding: 50.52 Most Recent Split Date: (:1) Beta: Market Capitalization: $512.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/27/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -125.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - -4.31 09/30/21 - -3.74 ROA 03/31/22 - - 12/31/21 - -4.26 09/30/21 - -3.69 Current Ratio 03/31/22 - - 12/31/21 - 101.80 09/30/21 - 140.46 Quick Ratio 03/31/22 - - 12/31/21 - 101.80 09/30/21 - 140.46 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 5.49 09/30/21 - 5.61 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©